SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:hh-30034"
 

Sökning: onr:"swepub:oai:DiVA.org:hh-30034" > European League Aga...

  • Gossec, L.Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Paris, France & Department of rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France (författare)

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update

  • Artikel/kapitelEngelska2016

Förlag, utgivningsår, omfång ...

  • 2015-12-07
  • London :BMJ Books,2016
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:hh-30034
  • https://urn.kb.se/resolve?urn=urn:nbn:se:hh:diva-30034URI
  • https://doi.org/10.1136/annrheumdis-2015-208337DOI
  • https://lup.lub.lu.se/record/8505458URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding by EULAR (grant CLI079).
  • BACKGROUND: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations.METHODS: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated.RESULTS: The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used.CONCLUSIONS: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion. © 2015 BMJ Publishing Group Ltd & European League Against Rheumatism.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Smolen, J. S.Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria & Second Department of Medicine, Hietzing Hospital, Vienna, Austria,Department of Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany (författare)
  • Ramiro, S.Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands (författare)
  • de Wit, M.EULAR, representing People with Arthritis/Rheumatism in Europe (PARE), London, United Kingdom,European League Against Rheumatism,A.DI.PSO. (Associazione per la Difesa degli Psoriasici)—PE.Pso.POF (Pan European Psoriasis Patients’ Organization Forum), Rome, Italy,Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom (författare)
  • Cutolo, M.Research Laboratory and Clinical Division of Rheumatology, Department of Internal Medicine, University of Genova, Viale Benedetto, Italy (författare)
  • Dougados, M.Medicine Faculty, Paris Descartes University, Paris, France & Rheumatology B Department, APHP, Cochin Hospital, Paris, France (författare)
  • Emery, P.Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom (författare)
  • Landewé, R.Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands & Atrium Medical Center, Heerlen, The Netherlands,Amsterdam Rheumatology and Immunology Center (författare)
  • Oliver, S.North Devon, United Kingdom (författare)
  • Aletaha, D.Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria (författare)
  • Betteridge, N.EULAR, representing People with Arthritis/Rheumatism in Europe (PARE), London, United Kingdom (författare)
  • Braun, J.Rheumazentrum Ruhrgebiet, Herne and Ruhr-Universität Bochum, Herne, Germany (författare)
  • Burmester, G.Department of Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Germany (författare)
  • Cañete, J. D.Arthritis Unit, Department of Rheumatology, Hospital Clínic and IDIBAPS, Barcelona, Spain (författare)
  • Damjanov, N.Belgrade University School of Medicine, Belgrade, Serbia (författare)
  • FitzGerald, O.Department of Rheumatology, St. Vincent's University Hospital and Conway Institute, University College Dublin, Dublin, Ireland (författare)
  • Haglund, Emma,1970-Lund University,Lunds universitet,Högskolan i Halmstad,Bio- och miljösystemforskning (BLESS),Section of Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-ehg (författare)
  • Helliwell, P.Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom (författare)
  • Kvien, T. K.Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway (författare)
  • Lories, R.Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, KU Leuven, Belgium & Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium (författare)
  • Luger, T.Department of Dermatology, University Hospital Münster, Münster, Germany (författare)
  • Maccarone, M.A.DI.PSO. (Associazione per la Difesa degli Psoriasici)—PE.Pso.POF (Pan European Psoriasis Patients’ Organization Forum), Rome, Italy (författare)
  • Marzo-Ortega, H.Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom (författare)
  • McGonagle, D.Leeds NIHR Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom (författare)
  • McInnes, I. B.Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom (författare)
  • Olivieri, I.Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy (författare)
  • Pavelka, K.Institute and Clinic of Rheumatology Charles University Prague, Czech Republic (författare)
  • Schett, G.Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany (författare)
  • Sieper, J.Department of Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany (författare)
  • van den Bosch, F.Ghent University Hospital, Ghent, Belgium (författare)
  • Veale, D. J.Centre for Arthritis and Rheumatic Disease, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland (författare)
  • Wollenhaupt, J.Schoen Klinik Hamburg, Rheumatology and Clinical Immunology, Hamburg, Germany (författare)
  • Zink, A.Department of Rheumatology and Clinical Immunology, German Rheumatism Research Centre Berlin, Charité—University Medicine Berlin, Germany (författare)
  • van der Heijde, D.Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands (författare)
  • Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Paris, France & Department of rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, FranceDivision of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria & Second Department of Medicine, Hietzing Hospital, Vienna, Austria (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Annals of the Rheumatic DiseasesLondon : BMJ Books75:3, s. 499-5100003-49671468-2060

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy